XML 52 R28.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Note 1 - Nature of the Business Group Internal Restructuring (Details Textual) $ / shares in Units, ¥ in Thousands |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 20, 2015 USD ($) shares | Jul. 20, 2015 CNY (¥) shares | May 06, 2015 USD ($) | May 06, 2015 CNY (¥) | Apr. 13, 2015 USD ($) $ / shares shares | Mar. 30, 2015 USD ($) | Mar. 30, 2015 CNY (¥) | Sep. 30, 2016 USD ($) $ / shares shares | Aug. 31, 2015 USD ($) | Aug. 31, 2015 CNY (¥) | Apr. 30, 2015 USD ($) shares | Mar. 31, 2015 shares | Jan. 31, 2015 | Dec. 31, 2014 USD ($) | Dec. 31, 2014 CNY (¥) | Dec. 31, 2012 USD ($) | Dec. 31, 2012 CNY (¥) | Dec. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Aug. 31, 2015 CNY (¥) | Jul. 02, 2015 | Apr. 10, 2015
Stock Issued During Period, Value, New Issues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,250,000 | $ 16,000,000 |  |  |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,908,000 | 10,970,000 |  |  |
Cash |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,687,000 | 10,821,000 |  |  |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,609,000 | $ 1,312,000 |  |  |
Sale to Third-party Investors [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  |  |  |  |  | 1,129,628 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  |  |  |  |  | $ 15,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares Issued, Price Per Share | $ / shares |  |  |  |  |  |  |  | $ 13.50 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mr. Dong Liang [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  |  |  |  |  |  |  |  | 320,000 |  |  |  |  |  |  |  |  |  |  |
Founders [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  |  |  |  |  |  |  |  |  | 13,429,997 |  |  |  |  |  |  |  |  |  |
Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  |  | 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchun Biotech [Member] | Internal Restructuring Plan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares | 60,000 | 60,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Beijing Sangel Fang Sheng Venture Capital [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues | shares |  |  |  |  | 1,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Value, New Issues |  |  |  |  | $ 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares Issued, Price Per Share | $ / shares |  |  |  |  | $ 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchun Biotech [Member] | Drug Research [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets | $ 1,513,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash | 1,201,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Due from Related Parties | 312,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Liabilities | 9,705,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shanghai Fosun [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments | $ 1,611,000 | ¥ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments, Shares | shares | 240,000 | 240,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
One Founder [Member] | Shenzhen Sangel Sino-euro Venture Capital [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transfer of Stock, Shares | shares |  |  |  |  |  |  |  |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |
Transfer of Stock, Value |  |  |  |  |  |  |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |
Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage Sold |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, Acquisitions | shares | 300,000 | 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BeyondSpring U.S. [Member] | Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |
BeyondSpring U.S. [Member] | Founders [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage | 85.02% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchun Pharma [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments | $ 2,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Assets | $ 1,347,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchun Pharma [Member] | Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage | 9.09% |  |  |  |  | 9.09% | 9.09% |  |  |  |  |  |  |  |  | 90.91% | 90.91% |  |  |  | 100.00% | 9.09%
Equity Method Investment, Ownership Percentage Acquired |  |  |  |  |  | 9.09% | 9.09% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  |  | $ 1,611,000 | ¥ 10,000 |  |  |  |  |  |  | $ 3,212,000 | ¥ 20,000 |  |  |  |  |  |  |
Wanchun Pharma [Member] | Wanchun Biotech [Member] | Patents [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 16,042,000 | ¥ 100,000 |  |  |  |  |
Wanchun Pharma [Member] | Shanghai Fosun [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9.09% | 9.09% |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,212,000 | ¥ 20,000 | $ 1,604,000 | ¥ 10,000 |  |  |  |  |
Wanchunbulin [Member] | Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  | 40.00% | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchunbulin [Member] | Wanchun Biotech [Member] | Patents [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  | $ 5,290,000 | ¥ 32,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wanchunbulin [Member] | Wanchun Shenzhen [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  | 60.00% | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Equity Method Investments |  |  | $ 7,716,000 | ¥ 49,200 |  |  |  |  | $ 2,000,000 | ¥ 12,752 |  |  |  |  |  |  |  |  |  |  |  |
Wanchunbulin [Member] | Wanchun Shenzhen [Member] | Investing Additional Capital During the Next 5 Years [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual Obligation |  |  |  |  |  |  |  |  | $ 5,716,000 |  |  |  |  |  |  |  |  |  |  | ¥ 36,448 |  |
Contractual Obligation, Term of Agreement |  |  |  |  |  |  |  |  | 5 years | 5 years |  |  |  |  |  |  |  |  |  |  |  |
BVI Biotech [Member] | Wanchun Biotech [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |

X
- Definition The term during which the contractual obligation must be fulfilled. + References No definition available. + Details
Name: | bysi_ContractualObligationTermOfAgreement
Namespace Prefix: | bysi_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of equity method investment acquired during the period. + References No definition available. + Details
Name: | bysi_EquityMethodInvestmentOwnershipPercentageAcquired
Namespace Prefix: | bysi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership in equity method investment that was disposed of during the period. + References No definition available. + Details
Name: | bysi_EquityMethodInvestmentOwnershipPercentageSold
Namespace Prefix: | bysi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The shares associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References No definition available. + Details
Name: | bysi_PaymentsToAcquireEquityMethodInvestmentsShares
Namespace Prefix: | bysi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of stock shares transferred by certain entities. + References No definition available. + Details
Name: | bysi_TransferOfStockShares
Namespace Prefix: | bysi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The monetary value of stock transferred by certain entities. + References No definition available. + Details
Name: | bysi_TransferOfStockValue
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_Assets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_Cash
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.3) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10(3)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_DueFromRelatedParties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66011266&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_Liabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares of stock issued during the period pursuant to acquisitions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bysi_SaleToThirdPartyInvestorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=bysi_MrDongLiangMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bysi_FoundersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bysi_WanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RestructuringPlanAxis=bysi_InternalRestructuringPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bysi_BeijingSangelFangShengVentureCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_WanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bysi_DrugResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_ShanghaiFosunMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_OneFounderMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=bysi_ShenzhenSangelSinoeuroVentureCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_WanchunBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_BeyondSpringUSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_FoundersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_WanchunPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_WanchunbulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bysi_WanchunShenzhenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bysi_InvestingAdditionalCapitalDuringTheNext5YearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bysi_BVIBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |